Elevated MED28 expression predicts poor outcome in women with breast cancer
By: Nam K Yoon , Erin L Maresh , Yahya Elshimali , Ai Li , Steve Horvath , David B Seligson , David Chia and Lee Goodglick

BMC Cancer 2010, 10:335 doi:10.1186/1471-2407-10-335
Published: 28 June 2010

Abstract (Provisional)

Background

MED28 (also known as EG-1 and magicin) has been implicated in transcriptional control, signal regulation, and cell proliferation. MED28 has also been associated with tumor progression in in vitro and in vivo models. Here we examined the association of MED28 expression with human breast cancer progression.

Methods

Expression of MED28 protein was determined on a population basis using a high-density tissue microarray consisting of 210 breast cancer patients. The association and validation of MED28 expression with histopathological subtypes and disease outcome was assessed.

Results

MED28 protein expression levels were increased in ductal carcinoma in situ and invasive ductal carcinoma of the breast compared to non-malignant glandular and ductal epithelium. Moreover, MED28 was a predictor of disease outcome in both univariate and multivariate analyses with higher expression predicting a greater risk of disease-related death.

Conclusions

We have demonstrated that MED28 expression is increased in breast cancer. In addition, MED28 is a novel, independent prognostic indicator of survival for breast cancer.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production







Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements